VU 591 hydrochlorideSelective Kir1.1 (ROMK) inhibitor CAS# 1315380-70-1 |
2D Structure
- VU 0361737
Catalog No.:BCC4596
CAS No.:1161205-04-4
- Ifenprodil Tartrate
Catalog No.:BCC4589
CAS No.:23210-58-4
- VU 0364770
Catalog No.:BCC4597
CAS No.:61350-00-3
- MK-801 (Dizocilpine)
Catalog No.:BCC4591
CAS No.:77086-21-6
- Latrepirdine
Catalog No.:BCC4541
CAS No.:97657-92-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1315380-70-1 | SDF | Download SDF |
PubChem ID | 90488918 | Appearance | Powder |
Formula | C16H13ClN6O5 | M.Wt | 404.76 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 16.67 mg/mL (41.18 mM; Need ultrasonic) | ||
Chemical Name | 6-nitro-2-[(6-nitro-1H-benzimidazol-2-yl)methoxymethyl]-1H-benzimidazole;hydrochloride | ||
SMILES | C1=CC2=C(C=C1[N+](=O)[O-])NC(=N2)COCC3=NC4=C(N3)C=C(C=C4)[N+](=O)[O-].Cl | ||
Standard InChIKey | PXLOUHLPDHEXCC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H12N6O5.ClH/c23-21(24)9-1-3-11-13(5-9)19-15(17-11)7-27-8-16-18-12-4-2-10(22(25)26)6-14(12)20-16;/h1-6H,7-8H2,(H,17,19)(H,18,20);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective renal outer medullary potassium channel (Kir1.1, ROMK) antagonist (IC50 = 300 nM). Thought to block the intracellular pore of the Kir1.1 channel. Exhibits no effect on Kir7.1 at concentrations up to 10 μM; does not inhibit Kir2.1, Kir2.3 or Kir4.1. Displays similar potency to VU 590 . |
VU 591 hydrochloride Dilution Calculator
VU 591 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.4706 mL | 12.353 mL | 24.706 mL | 49.412 mL | 61.765 mL |
5 mM | 0.4941 mL | 2.4706 mL | 4.9412 mL | 9.8824 mL | 12.353 mL |
10 mM | 0.2471 mL | 1.2353 mL | 2.4706 mL | 4.9412 mL | 6.1765 mL |
50 mM | 0.0494 mL | 0.2471 mL | 0.4941 mL | 0.9882 mL | 1.2353 mL |
100 mM | 0.0247 mL | 0.1235 mL | 0.2471 mL | 0.4941 mL | 0.6176 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- NPEC-caged-(1S,3R)-ACPD
Catalog No.:BCC7653
CAS No.:1315379-60-2
- Rac1 Inhibitor F56, control peptide
Catalog No.:BCC5887
CAS No.:1315378-77-8
- pep2-SVKE
Catalog No.:BCC5785
CAS No.:1315378-76-7
- MNI caged kainic acid
Catalog No.:BCC7297
CAS No.:1315378-75-6
- Bax inhibitor peptide, negative control
Catalog No.:BCC2395
CAS No.:1315378-74-5
- PDZ1 Domain inhibitor peptide
Catalog No.:BCC5883
CAS No.:1315378-73-4
- Scrambled 10Panx
Catalog No.:BCC1246
CAS No.:1315378-72-3
- TCS 184
Catalog No.:BCC5899
CAS No.:1315378-71-2
- pep2-AVKI
Catalog No.:BCC5787
CAS No.:1315378-69-8
- pep2-EVKI
Catalog No.:BCC5786
CAS No.:1315378-67-6
- NG25
Catalog No.:BCC1799
CAS No.:1315355-93-1
- B-Raf inhibitor
Catalog No.:BCC1437
CAS No.:1315330-11-0
- Triumbelletin
Catalog No.:BCN6779
CAS No.:131559-54-1
- Camelliaside B
Catalog No.:BCN3872
CAS No.:131573-90-5
- Calystegine A3
Catalog No.:BCN1884
CAS No.:131580-36-4
- Betulinaldehyde
Catalog No.:BCN1249
CAS No.:13159-28-9
- Amyloid Beta-peptide (25-35) (human)
Catalog No.:BCC1027
CAS No.:131602-53-4
- (+)-Pteryxin
Catalog No.:BCN3470
CAS No.:13161-75-6
- Rocilinostat (ACY-1215)
Catalog No.:BCC2144
CAS No.:1316214-52-4
- ACY-241
Catalog No.:BCC6460
CAS No.:1316215-12-9
- OPC 21268
Catalog No.:BCC7812
CAS No.:131631-89-5
- Chalepensin
Catalog No.:BCN7334
CAS No.:13164-03-9
- Turmeronol A
Catalog No.:BCN6777
CAS No.:131651-37-1
- 8-(1-Chloro-2-hydroxy-3-methylbut-3-enyl)-7-methoxycoumarin
Catalog No.:BCN7058
CAS No.:131652-35-2
Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel.[Pubmed:20926757]
Mol Pharmacol. 2011 Jan;79(1):42-50.
The renal outer medullary potassium (K+) channel, ROMK (Kir1.1), is a putative drug target for a novel class of loop diuretic that would lower blood volume and pressure without causing hypokalemia. However, the lack of selective ROMK inhibitors has hindered efforts to assess its therapeutic potential. In a high-throughput screen for small-molecule modulators of ROMK, we previously identified a potent and moderately selective ROMK antagonist, 7,13-bis(4-nitrobenzyl)-1,4,10-trioxa-7,13-diazacyclopentadecane (VU590), that also inhibits Kir7.1. Because ROMK and Kir7.1 are coexpressed in the nephron, VU590 is not a good probe of ROMK function in the kidney. Here we describe the development of the structurally related inhibitor 2,2'-oxybis(methylene)bis(5-nitro-1H-benzo[d]imidazole) (VU591), which is as potent as VU590 but is selective for ROMK over Kir7.1 and more than 65 other potential off-targets. VU591 seems to block the intracellular pore of the channel. The development of VU591 may enable studies to explore the viability of ROMK as a diuretic target.